0A9E Stock Overview A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for CureVac Historical stock prices Current Share Price US$2.88 52 Week High US$5.28 52 Week Low US$2.23 Beta 2.59 1 Month Change 9.76% 3 Month Change -7.52% 1 Year Change -29.58% 3 Year Change -92.25% 5 Year Change n/a Change since IPO -97.41%
Recent News & Updates
Forecast to breakeven in 2024 Nov 14
CureVac N.V. to Report Q3, 2024 Results on Nov 12, 2024 Nov 07
Curevac N.V. Appoints Axel Sven Malkomes as Chief Financial Officer, Effective November 11, 2024 Nov 05
CureVac N.V. to Present at the Society for Immunotherapy of Cancer 39th Annual Meeting Oct 28
CureVac N.V. to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress Sep 09
Second quarter 2024 earnings released: €0.32 loss per share (vs €0.30 loss in 2Q 2023) Aug 17 See more updates
Forecast to breakeven in 2024 Nov 14
CureVac N.V. to Report Q3, 2024 Results on Nov 12, 2024 Nov 07
Curevac N.V. Appoints Axel Sven Malkomes as Chief Financial Officer, Effective November 11, 2024 Nov 05
CureVac N.V. to Present at the Society for Immunotherapy of Cancer 39th Annual Meeting Oct 28
CureVac N.V. to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress Sep 09
Second quarter 2024 earnings released: €0.32 loss per share (vs €0.30 loss in 2Q 2023) Aug 17 CureVac N.V. Announces Pierre Kemula, Chief Financial Officer, to Step Down At the End of His Term October 31, 2024
CureVac N.V. to Report Q2, 2024 Results on Aug 15, 2024 Aug 14
CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board Jun 25
CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK May 29
New major risk - Financial position May 24
CureVac N.V. to Report Q1, 2024 Results on May 23, 2024 May 23
Full year 2023 earnings released: €1.18 loss per share (vs €1.32 loss in FY 2022) Apr 26 CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024
CureVac N.V. to Report Q4, 2023 Results on Apr 24, 2024 Apr 20
CureVac N.V. Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK Apr 04
New major risk - Share price stability Feb 15 CureVac N.V. Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE Dec 19
Third quarter 2023 earnings released: €0.25 loss per share (vs €0.25 loss in 3Q 2022) Nov 15
CureVac N.V. Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK Nov 02
CureVac N.V. to Report Q3, 2023 Results on Nov 14, 2023 Nov 01
Second quarter 2023 earnings released: €0.30 loss per share (vs €0.31 loss in 2Q 2022) Aug 20
CureVac N.V. to Report Q2, 2023 Results on Aug 17, 2023 Aug 12
CureVac N.V. Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 Mrna Vaccine Candidates Developed in Collaboration with GSK Aug 02
CureVac N.V. Announces Executive Changes Jul 15
New major risk - Share price stability Jun 28 CureVac N.V. Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
First quarter 2023 earnings released: €0.27 loss per share (vs €0.081 loss in 1Q 2022) May 31
CureVac N.V., Annual General Meeting, Jun 19, 2023 May 31
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK May 09
Full year 2022 earnings released: €1.32 loss per share (vs €2.21 loss in FY 2021) Apr 27
CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer Feb 02
CureVac N.V. Announces Positive Data in Older Adults from Covid-19 and Flu mRNA Vaccine Development Programs Jan 31
Now 25% undervalued Jan 12
CureVac N.V. Announces CEO Changes Jan 10
Third quarter 2022 earnings released: €0.25 loss per share (vs €0.77 loss in 3Q 2021) Nov 19
CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102 Nov 12
CureVac N.V. to Report Q3, 2022 Results on Nov 16, 2022 Nov 11
Second quarter 2022 earnings released: €0.31 loss per share (vs €0.82 loss in 2Q 2021) Aug 20
No longer forecast to breakeven Aug 20 CureVac Announces Executive Changes
CureVac N.V. Announces Board Changes Jun 23
CureVac N.V. (NasdaqGM:CVAC) acquired Frame Therapeutics B.V. for €32 million. Jun 10
CureVac N.V. Announces Changes of CDO Jun 09
CureVac N.V., Annual General Meeting, Jun 22, 2022 Jun 02
Full year 2021 earnings released: €2.21 loss per share (vs €0.98 loss in FY 2020) May 01
Forecast breakeven date pushed back to 2024 Apr 27
CureVac N.V. to Report Q4, 2021 Results on Apr 28, 2022 Apr 23
CureVac N.V Announces Preclinical Data Demonstrating Immune Responses and Protective Efficacy of Bivalent Second-Generation COVID-19 Vaccine Candidate Jointly Developed with GSK Apr 22
CureVac N.V. and GSK Start Clinical Development of Second-Generation Covid-19 Vaccine Candidate, CV2CoV Apr 01
CureVac N.V. Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK Feb 11
Forecast breakeven date pushed back to 2024 Jan 30
Forecast breakeven date pushed back to 2023 Jan 19
CureVac Streamlines European Network for mRNA Product Manufacturing Sep 16
CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic Aug 31
Forecast breakeven moved forward to 2021 Aug 17
CureVac Announces that Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study Aug 17
CureVac N.V. Announces Results from the Final Analysis of its 40,000 Subject International Pivotal Phase 2b/3 Study of the First-Generation COVID-19 Vaccine Candidate, CVnCoV Jul 01
CureVac N.V. Announces Results of the Second Interim Analysis of its International Pivotal Phase 2b/3 Study in Approximatively 40,000 Subjects Jun 17
CureVac N.V.’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation May 29 Shareholder Returns 0A9E GB Biotechs GB Market 7D -9.6% -4.2% -2.6% 1Y -29.6% -24.5% 2.4%
See full shareholder returns
Return vs Industry: 0A9E underperformed the UK Biotechs industry which returned -24.5% over the past year.
Return vs Market: 0A9E underperformed the UK Market which returned 2.4% over the past year.
Price Volatility Is 0A9E's price volatile compared to industry and market? 0A9E volatility 0A9E Average Weekly Movement 7.3% Biotechs Industry Average Movement 6.9% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0A9E's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A9E's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer.
Show more CureVac N.V. Fundamentals Summary How do CureVac's earnings and revenue compare to its market cap? 0A9E fundamental statistics Market cap US$643.78m Earnings (TTM ) -US$290.52m Revenue (TTM ) US$68.72m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0A9E income statement (TTM ) Revenue €65.86m Cost of Revenue €152.13m Gross Profit -€86.27m Other Expenses €192.16m Earnings -€278.43m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -1.24 Gross Margin -131.00% Net Profit Margin -422.77% Debt/Equity Ratio 0%
How did 0A9E perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 23:22 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources CureVac N.V. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Charlie Yang BofA Global Research Geoffrey Meacham BofA Global Research Martin Auster Credit Suisse
Show 7 more analysts 